Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIBOLARIS: Ribociclib and Endocrine Therapy in High-risk ER+/HER2- Breast Cancer
NCT05296746Phase 2Active, not recruiting
- Sponsor
- SOLTI
- Start
- May 2022
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ribociclib in breast cancer, sponsored by SOLTI. Started May 2022; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05296746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296746.